NASDAQ:ADAP - Adaptimmune Therapeutics Stock Price, Forecast & News

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.03. The biotechnology company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $7 million. View Adaptimmune Therapeutics' Earnings History.

Adaptimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Adaptimmune Therapeutics.

7 brokerages have issued 12 month price objectives for Adaptimmune Therapeutics' stock. Their forecasts range from $4.15 to $8.00. On average, they anticipate Adaptimmune Therapeutics' share price to reach $6.03 in the next twelve months. This suggests a possible upside of 63.9% from the stock's current price. View Analyst Price Targets for Adaptimmune Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adaptimmune Therapeutics.

News stories about ADAP stock have trended somewhat negative on Monday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adaptimmune Therapeutics earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Adaptimmune Therapeutics.

Adaptimmune Therapeutics saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 1,530,000 shares, a drop of 35.2% from the December 31st total of 2,360,000 shares. Based on an average daily volume of 1,590,000 shares, the short-interest ratio is currently 1.0 days. Currently, 1.7% of the company's shares are short sold. View Adaptimmune Therapeutics' Current Options Chain.

Some companies that are related to Adaptimmune Therapeutics include Regenxbio (RGNX), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), Mesoblast (MESO), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Krystal Biotech (KRYS), BAVARIAN NORDIC/S (BVNRY), Sangamo Therapeutics (SGMO), Vericel (VCEL) and Proteon Therapeutics (PRTO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Second Sight Medical Products (EYES), Brainstorm Cell Therapeutics (BCLI), BlackRock (BLK), Shopify (SHOP), Cara Therapeutics (CARA), Chipotle Mexican Grill (CMG) and Micron Technology (MU).

(ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADAP stock can currently be purchased for approximately $3.68.

Adaptimmune Therapeutics has a market capitalization of $385.26 million and generates $59.51 million in revenue each year. The biotechnology company earns $-95,510,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.View Additional Information About Adaptimmune Therapeutics.

The official website for Adaptimmune Therapeutics is http://www.adaptimmune.com/.

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]